In a 75-year-old woman taking oral estradiol 2 mg twice daily (total 4 mg per day), is hormone therapy indicated for menopausal symptoms?

This Dose is NOT Indicated and Should Be Discontinued or Dramatically Reduced

At age 75, this patient is well outside the therapeutic window for menopausal hormone therapy, and the dose of 4 mg daily estradiol is dangerously high—approximately 2-4 times the standard dose—placing her at significantly increased risk for stroke, venous thromboembolism, and dementia with minimal to no benefit.

Age-Based Contraindication

The Endocrine Society guidelines explicitly state that benefits exceed risks only for symptomatic postmenopausal women under age 60 or within 10 years of menopause onset 1. At 75 years old, this patient is:

• At least 25+ years post-menopause (assuming menopause at age 50)
• Well beyond the 10-year therapeutic window
• In the age group where absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia are substantially elevated 2

The 2022 NAMS position statement reinforces that for women initiating or continuing hormone therapy more than 10 years from menopause onset or aged older than 60 years, the benefit-risk ratio is unfavorable 2.

Excessive Dosing

The FDA-approved dosing for menopausal symptoms is 1-2 mg daily of oral estradiol, adjusted to the minimal effective dose 3. This patient is taking:

• 4 mg daily total dose (2 mg twice daily)
• This is 2-4 times the recommended starting dose
• Even for palliation of metastatic breast cancer, the dose is only 10 mg three times daily—a completely different indication 3

Immediate Clinical Actions Required

You should:

1. Verify the indication: Determine why she was started on this therapy and whether she still has active symptoms requiring treatment

   • If asymptomatic: Discontinue entirely
   • If she has genitourinary symptoms only: Switch to low-dose vaginal estrogen (10 mcg estradiol tablet twice weekly) 1
   • If she has persistent vasomotor symptoms (unlikely at this age): Consider non-hormonal alternatives (SSRIs, SNRIs, gabapentin)

2. Assess cardiovascular and thrombotic risk: Screen for history of stroke, MI, VTE, or dementia risk factors—all of which are contraindications at this age 3

3. Check for endometrial protection: If she has a uterus, she requires progestogen therapy to prevent endometrial cancer, which appears to be missing from this regimen 3

4. Taper rather than abrupt cessation: To minimize rebound symptoms, consider gradual dose reduction over 2-3 months

Critical Safety Concerns

The WHI study demonstrated that in older postmenopausal women (50-79 years), hormone therapy increased risks of:

• Myocardial infarction
• Stroke
• Invasive breast cancer
• Pulmonary emboli
• Deep vein thrombosis 3

The WHIMS substudy showed increased risk of probable dementia in women ≥65 years taking estrogen plus progestogen 3. Your 75-year-old patient falls squarely into this high-risk category.

Common Pitfall to Avoid

Do not assume that because she has been on this therapy for years without apparent harm that it is safe to continue. The cumulative risks increase with duration, and longer durations of therapy should only be for documented indications with periodic reevaluation 2. At 75, there is virtually no indication for systemic estrogen at any dose, let alone this excessive one.

The only potential exception would be if she has documented premature ovarian insufficiency or surgical menopause before age 40, in which case hormone therapy is recommended until the natural age of menopause (~51 years)—but even then, she would be 24+ years past that endpoint.